You are here: Industry Insights > billion

News List

From Ruxolitinib to Upadacitinib, the USD 5 Billion Blue Ocean Market Ushers a Fierce Battle of JAK Inhibitors Spuer 203
May 06, 2024
Medical System from Incyte has initiated Phase III clinical trials of vitiligo in China.
With Whole Line Reduction or R&D Difficulties, Projects of Billions of Dollars Are Stranded - Analysis on Transnational Pharmaceutical Companies Terminating R&D Projects in H1 of the Year PharmaSources/Spuer 203
August 28, 2023
Sales volume of Dupixent reaching USD 5.35 billion in H1 of the year, setting off a R&D boom of IL-4R in China PharmaSources/Yefenghong
August 28, 2023
Under the influence of Dupixent, there is a R&D boom of IL-4 targets in China.
Domestic Enterprises Have Fully Laid out the Blue Ocean of US$10 Billion, and CAR-T Therapy Must Overcome the Achilles' Heel of Solid Tumor 203 Spuer/PharmaSources
August 07, 2023
The solid tumor is one of the two most deeply developed fields in CAR-T therapy, thus it is extremely urgent to overcome solid tumor in CAR-T therapy, considering domestic market access policy and current biomedical capital environment.
What is the Confidence of this Pharmaceutical Company To Target its Sales Peak of CNY 10 Billion? Xiaobin/PharmaSources
August 07, 2023
Recently, at Everest Medicines' investor exchange activities, the management led by CEO Luo Yongqing put forward the target of "realizing the marketing of four commercial products in a short time, with a sales peak of CNY 10 billion".
More ADCs made in China, Led by Kelun Pharmaceutical, Expanding into the World Market with a Total Transaction Amount of over USD 20 billion Yi/PharmaSources
June 06, 2023
More ADCs made in China, led by Kelun Pharmaceutical, expanding into the world market with a total transaction amount of over USD 20 billion.
Global ICIs Market Exceeds USD 30 Billion in 2021, with its Number and Indications Approved Entering an Outbreak Period Yi
April 11, 2022
Lately, Opdualag, a fixed-dose compound preparation of BMS consisting of LAG-3 inhibitor relatlimab and PD-1 monoclonal antibody nivolumab, was approved by FDA for the treatment of adults and pediatric patients aged 12 years and older with unresectable or
Bivalent HPV Vaccine of Walvax Approved for Marketing: Who Will be the Leader of the Market Valuing RMB 100 billion? Yefenghong
April 11, 2022
Bivalent HPV Vaccine of Walvax Approved for Marketing: Who Will be the Leader of the Market Valuing RMB 100 billion?
With Sky-high Price, CAR-T Therapy Sold at Least USD1.709 Billion in 2021 PharmaSources/Yi
March 30, 2022
Currently, six CART-cell immunotherapies have been approved in China and abroad, as shown in the table below. Except for Abecma, the other five therapies are all targeted at CD19.
The Boosting Bispecific Antibody Therapeutics Market: Market Size Exceeded USD3.5 Billion by 2021 PharmaSources/Yi
March 30, 2022
So far this year, there has been good news on the bispecific antibody therapeutics market.